Overexpression of FOXM1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation, Migration and Invasion in Epithelial Ovarian Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2014 Jun 3

PMID 24885308

Citations 54

Authors

Ning Wen

Yu Wang

Li Wen

Shu-Hua Zhao

Zhen-Hua Ai

Yi Wang

Bo Wu

Huai-Xiu Lu

Hong Yang

Wen-Chao Liu

Yu Li

Affiliations

Soon will be listed here.

Abstract

Background: The Forkhead box M1 (FOXM1), an important regulator of cell differentiation and proliferation, is overexpressed in a number of aggressive human carcinomas. The purpose of this study was to examine the expression levels of FOXM1 in epithelial ovarian cancer (EOC), to identify the relationship between FOXM1 expression and patient survival, and to investigate the role of FOXM1 in human ovarian cancer development.

Methods: Immunohistochemical analysis for FOXM1 was performed in a total of 158 ovarian tissue specimens, all with linked clinical outcome data. Kaplan-Meier method and Cox proportional hazards analysis were used to relate FOXM1 expression to clinicopathological variables and to progression-free survival (PFS) and overall survival (OS). In vitro studies were performed to determine the function of FOXM1 in cell proliferation, migration and invasion in EOC cells using pcDNA3.1-FOXM1 and FOXM1 shRNA.

Results: Elevated FOXM1 levels were associated with lymph node metastasis (P = 0.009), but not with age, FIGO stage, histological grade and histological type. Patients with high expression of FOXM1 had poorer PFS (P = 0.0001) and OS (P < 0.0001) than patients with low expression of FOXM1. Furthermore, multivariate analyses indicated that FOXM1 positivity was an independent prognostic factor for PFS (P = 0.046) and OS (P = 0.022), respectively. Overexpression of FOXM1 increased expression and activity of matrix metalloproteinase-2 (MMP-2), MMP-9 and vascular endothelial growth factor-A (VEGF-A), and cancer cell proliferation, migration and invasion of HO-8910 cells, whereas knockdown of FOXM1 reduced expression and activity of MMP-2, MMP-9 and VEGF-A, and cancer cell proliferation, migration and invasion of HO-8910 PM cells.

Conclusions: Our results suggest that FOXM1 expression is likely to play important roles in EOC development and progression. FOXM1 expression is a potential prognostic factor for PFS and OS, and it could be a novel treatment target in EOC patients.

Citing Articles

The conformation of FOXM1 homodimers in vivo is crucial for regulating transcriptional activities.

Hsu C, Yao X, Chen S, Tsuo T, Wang I Nucleic Acids Res. 2024; 52(22):13625-13643.

PMID: 39535028 PMC: 11662942. DOI: 10.1093/nar/gkae988.

Novel benzothiazole/benzothiazole thiazolidine-2,4-dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies.

Abusharkh K, Comert Onder F, Cinar V, Onder A, Sikik M, Hamurcu Z Arch Pharm (Weinheim). 2024; 357(12):e2400504.

PMID: 39318080 PMC: 11610698. DOI: 10.1002/ardp.202400504.

MicroRNAs role in telomere length maintenance and telomerase activity in tumor cells.

Bortoletto S, Nunes-Souza E, Marchi R, Ruthes M, Okano L, Tofolo M J Mol Med (Berl). 2024; 102(9):1089-1100.

PMID: 39042290 DOI: 10.1007/s00109-024-02467-z.

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.

Vorderbruggen M, Velazquez-Martinez C, Natarajan A, Karpf A Int J Mol Sci. 2024; 25(10).

PMID: 38791105 PMC: 11121112. DOI: 10.3390/ijms25105067.

The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.

Wei Y, Chen Z, Li Y, Song K Oncogene. 2024; 43(20):1565-1578.

PMID: 38561505 DOI: 10.1038/s41388-024-03015-2.

References

Hua H, Li M, Luo T, Yin Y, Jiang Y . Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011; 68(23):3853-68. PMC: 11114831. DOI: 10.1007/s00018-011-0763-x. View

Wang Z, Banerjee S, Kong D, Li Y, Sarkar F . Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007; 67(17):8293-300. DOI: 10.1158/0008-5472.CAN-07-1265. View

Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A . VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003; 161(6):1163-77. PMC: 2172999. DOI: 10.1083/jcb.200302047. View

Vihinen P, Kahari V . Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002; 99(2):157-66. DOI: 10.1002/ijc.10329. View

Xu N, Jia D, Chen W, Wang H, Liu F, Ge H . FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One. 2013; 8(3):e59412. PMC: 3607616. DOI: 10.1371/journal.pone.0059412. View

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K . Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol. 2012; 20(3):1035-43. DOI: 10.1245/s10434-012-2680-0. View

Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D . Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009; 69(8):3501-9. PMC: 4087044. DOI: 10.1158/0008-5472.CAN-08-3045. View

Wang Y, Wen L, Zhao S, Ai Z, Guo J, Liu W . FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer. 2012; 79(2):173-9. DOI: 10.1016/j.lungcan.2012.10.019. View

Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z . Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res. 1999; 18(2):233-9. View

10.

Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown L, Detmar M . VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005; 201(7):1089-99. PMC: 2213132. DOI: 10.1084/jem.20041896. View

11.

Laoukili J, Stahl M, Medema R . FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 2006; 1775(1):92-102. DOI: 10.1016/j.bbcan.2006.08.006. View

12.

Ochi Y, Atsumi S, Aoyagi T, Umezawa K . Inhibition of tumor cell invasion in the Boyden chamber assay by a mannosidase inhibitor, mannostatin A. Anticancer Res. 1993; 13(5A):1421-4. View

13.

Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S . FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat. 2009; 122(2):337-46. DOI: 10.1007/s10549-009-0572-1. View

14.

Wierstra I . FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013; 119:191-419. DOI: 10.1016/B978-0-12-407190-2.00016-2. View

15.

Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, Abduljabbar A . Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am J Pathol. 2011; 178(2):537-47. PMC: 3070566. DOI: 10.1016/j.ajpath.2010.10.020. View

16.

Schmalfeldt B, Prechtel D, HARTING K, Spathe K, Rutke S, Konik E . Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7(8):2396-404. View

17.

Liu M, Dai B, Kang S, Ban K, Huang F, Lang F . FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006; 66(7):3593-602. DOI: 10.1158/0008-5472.CAN-05-2912. View

18.

Laoukili J, Kooistra M, Bras A, Kauw J, Kerkhoven R, Morrison A . FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005; 7(2):126-36. DOI: 10.1038/ncb1217. View

19.

Xue Y, Xiao R, Long D, Zou X, Wang X, Zhang G . Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med. 2012; 10:200. PMC: 3492118. DOI: 10.1186/1479-5876-10-200. View

20.

Chan D, Yu S, Chiu P, Yao K, Liu V, Cheung A . Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008; 215(3):245-52. DOI: 10.1002/path.2355. View